These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21922134)

  • 1. Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Fujikawa H; Matsushita K; Okugawa Y; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Int J Oncol; 2012 Feb; 40(2):583-91. PubMed ID: 21922134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
    Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
    Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Inoue Y; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Uchida K; Mohri Y; Kusunoki M
    Int J Oncol; 2012 Nov; 41(5):1643-52. PubMed ID: 22923071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of CD133 and hypoxia inducible factor-1α gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Koike Y; Fujikawa H; Inoue Y; Miki C; Kusunoki M
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):323-32. PubMed ID: 20970309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy.
    Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Inoue Y; Kobayashi M; Miki C; Kusunoki M
    J Surg Oncol; 2012 May; 105(6):529-34. PubMed ID: 22006578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Okugawa Y; Fujikawa H; Matsushita K; Uchida K; Inoue Y; Kusunoki M
    Surg Today; 2012 May; 42(5):460-9. PubMed ID: 22072148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
    Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
    J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer.
    Yasuda H; Tanaka K; Saigusa S; Toiyama Y; Koike Y; Okugawa Y; Yokoe T; Kawamoto A; Inoue Y; Miki C; Kusunoki M
    Oncol Rep; 2009 Oct; 22(4):709-17. PubMed ID: 19724847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of stromal CD26 expression in rectal cancer after chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Apr; 21(2):350-358. PubMed ID: 26370256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.
    Phan LM; Fuentes-Mattei E; Wu W; Velazquez-Torres G; Sircar K; Wood CG; Hai T; Jimenez C; Cote GJ; Ozsari L; Hofmann MC; Zheng S; Verhaak R; Pagliaro L; Cortez MA; Lee MH; Yeung SC; Habra MA
    Cancer Res; 2015 Oct; 75(19):4131-42. PubMed ID: 26282167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression.
    Noguchi E; Saito N; Kobayashi M; Kameoka S
    Mol Med Rep; 2015 May; 11(5):3423-31. PubMed ID: 25592281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy.
    Li CF; He HL; Wang JY; Huang HY; Wu TF; Hsing CH; Lee SW; Lee HH; Fang JL; Huang WT; Chen SH
    J Clin Pathol; 2014 Dec; 67(12):1056-61. PubMed ID: 25271212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node metastases in rectal cancer after preoperative radiochemotherapy: impact of intramesorectal distribution and residual micrometastatic involvement.
    Sprenger T; Rothe H; Becker H; Beissbarth T; Homayounfar K; Gauss K; Kitz J; Wolff H; Scheel AH; Ghadimi M; Rödel C; Conradi LC; Liersch T
    Am J Surg Pathol; 2013 Aug; 37(8):1283-9. PubMed ID: 23851331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision.
    Lee JH; Jang HS; Kim JG; Cho HM; Shim BY; Oh ST; Yoon SC; Kim YS; Choi BO; Kim SH
    Ann Surg Oncol; 2012 Apr; 19(4):1213-21. PubMed ID: 21935746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological analysis of distal margin for rectal cancer after preoperative chemoradiation therapy.
    Nishioka M; Shimada M; Kurita N; Iwata T; Morimoto S; Yoshikawa K; Higashijima J; Miyatani T
    Hepatogastroenterology; 2012 Oct; 59(119):2142-6. PubMed ID: 22366527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal CXCR4 and CXCL12 expression is associated with distant recurrence and poor prognosis in rectal cancer after chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Yokoe T; Okugawa Y; Kawamoto A; Yasuda H; Inoue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2010 Aug; 17(8):2051-8. PubMed ID: 20177796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.